Table 7.
Means and SD for all patients and controls and separated into women and men for the State aR total scale and subscales (State rest/activity, State orthostatic-circulatory, State thermosweating and State digestive regulation) and Trait aR total and subscales (Trait rest/activity regulation, Trait orthostatic-circulatory, Trait digestive regulation).
| S-aR Total scale | S-Rest-activitiy aR | S-Orthostatic-circulatory aR | S-Thermo-sweating aR | S-Digestive aR | T-aR Total scale | T-Rest-activity aR | T-Orthostatic-circulatory aR | T-Digestive aR | |
|---|---|---|---|---|---|---|---|---|---|
| Study 1 | |||||||||
| Patients | |||||||||
| Mean all | 65.86 | 27.81 | 17.12 | 10.61 | 10.30 | 41.49 | 17.85 | 16.57 | 7.00 |
| (SD) | (9.20) | (5.11) | (2.83) | (3.21) | (2.86) | (5.70) | (3.51) | (2.72) | (1.53) |
| Mean women | 65.24 | 27.51 | 17.00 | 10.07 | 10.63 | 40.54 | 17.59 | 16.00 | 6.95 |
| (SD) | (8-77) | (4.94) | (2.97) | (2.95) | (2.97) | (5.54) | (3.37) | (2.67) | (1.49) |
| Mean men | 67.44 | 28.56 | 17.44 | 10.56 | 10.87 | 44. 14 | 18.53 | 18.07 | 7.12 |
| (SD) | (10.36) | (5.64) | (2.68) | (3.86) | (2.63) | (5.48) | (3.87) | (2.34) | (1.67) |
| Control | 73.65 | 32.96 | 17.70 | 11.51 | 11.47 | 43.36 | 19.55 | 16.41 | 7.51 |
| Mean all (SD) | (7.56) | (4.31) | (2.54) | (2.73) | (2.31) | (4.65) | (2.87) | (2.50) | (1.48) |
| Mean women | 73.27 | 32.39 | 17.78 | 11.37 | 11.73 | 42.45 | 18.90 | 16.03 | 7.59 |
| (SD) | (7.49) | (4.55) | (2.66) | (2.84) | (1.98) | (4.63) | (2.99) | (2.50) | (1.32) |
| Mean men | 74.62 | 34.44 | 17.50 | 10.81 | 11.87 | 42.45 | 18.90 | 16.03 | 7.59 |
| (SD) | (7.89) | (3.31) | (2.28) | (2.97) | (2.47) | (4.63) | (2.99) | (2.50) | (1.32) |
| p-value | < 0.001 | < 0.001 | 0.21 | 0.14 | 0.015 | 0.090 | 0.006 | 0.75 | 0.029 |
| Patients vs Control* | |||||||||
| Study 2 | |||||||||
| Breast cancer | 70.29 | 30.76 | 17.18 | 10.65 | 11.65 | 41.53 | 17.56 | 16.62 | 7.35 |
| group 1 T0 | (6.72) | (3.47) | (2.43) | (2.42) | (1.73) | (4.41) | (3.31) | (1.59) | (1.06) |
| Breast cancer | 67.50 | 28.94 | 17.19 | 10.81 | 10.50 | 40.25 | 17.50 | 16.06 | 6.76 |
| group 1 T1 | (10.59) | (6.16) | (3.51) | (2.74) | (2.66) | (6.54) | (3.60) | (3.11) | (1.60) |
| Breast cancer | 67.65 | 29.75 | 16.65 | 10.53 | 10.94 | 41.12 | 17.41 | 16.47 | 7.23 |
| group 1 T2 | (10.09) | (5.93) | (3.82) | (3.20) | (2.68) | (6.53) | (3.69) | (2.87) | (1.39) |
| Colorectal cancer | 73.39 | 31.27 | 18.38 | 12.44 | 11.09 | 43.83 | 19.08 | 17.25 | 7.38 |
| T0 | (8.62) | (5.24) | (2.28) | (2.48) | (2.88) | (4.13) | (2.86) | (1.77) | (1.64) |
| Colorectal cancer | 69.87 | 28.46 | 17.46 | 12.42 | 11.58 | 43.29 | 18.81 | 17.04 | 7.57 |
| T1 | (12.11) | (6.78) | (3.39) | (3.30) | (2.19) | (5.22) | (3.47) | (2.16) | (1.34) |
| Colorectal cancer | 71.25 | 30.20 | 16.91 | 12.36 | 11.74 | 43.67 | 18.95 | 17.04 | 7.71 |
| T2 | (10.04) | (5.99) | (3.45) | (1.91) | (1.42) | (5.13) | (3.42) | (2.07) | (1.00) |
| p-value T0 vs T1 ** | 0.010 | 0.001 | 0.243 | 0.413 | 0.325 | 0.079 | 0.226 | 0.061 | 0.306 |
| p-value T1 vs T2** | 0.484 | 0.061 | 0.106 | 0.395 | 0.114 | 0.243 | 0.432 | 0.222 | 0.119 |
Significant results are shown in bold.
*Exact U-Test (2-side) between Cancer group and healthy controls,
** Exact Wilcoxon-Test (1-side) used for pooled breast cancer and colorectal cancer and tests T0 (before chemotherapy) vs. T1 (1-5 days after third chemotherapy cycle) and T1 vs, T2 (4-8 weeks after the end of chemotherapy).
Significant differences (p < 0.05) are shown in bold.